1. Pfizer poised for drop after US$48B climb on COVID vaccine  BNN
  2. U.K. tests if COVID-19 vaccines might work better inhaled  CTV News
  3. Scientists from 5 countries question accuracy of Russia coronavirus vaccine data  Global News
  4. COVID-19: UAE vaccine strengthens fight against coronavirus | Editorials  Gulf News
  5. Pfizer stock rockets as potential COVID-19 vaccine delivery by end of 2020  Yahoo
  6. View Full coverage on Google News
Pfizer Inc.’s $48 billion gain in market value since late March, egged on by optimism for a successful Covid-19 vaccine, may soon hit a wall.

Pfizer poised for drop after US$48B climb on COVID vaccine - BNN Bloomberg

Pfizer is among the stocks driving the rally in US futures after CEO's optimistic announcement over vaccine.Pfizer is among the stocks driving the rally in US futures after CEO's optimistic announcement over vaccine.

Pfizer stock rockets as potential COVID-19 vaccine delivery by end of 2020

Pfizer is among the stocks driving the rally in US futures after CEO's optimistic announcement over vaccine.Pfizer is among the stocks driving the rally in US futures after CEO's optimistic announcement over vaccine.

Pfizer stock rockets as potential COVID-19 vaccine delivery by end of 2020

Germany says it is providing up to 750 million euros (US$892 million) to support three domestic pharmaceutical companies that are developing vaccines against the new coronavirus.Germany says it is providing up to 750 million euros (US$892 million) to support three domestic pharmaceutical companies that are developing vaccines against the new coronavirus.

Germany boosts own vaccine makers in race for COVID-19 jab | CTV News

Albert Bourla, the CEO of Pfizer, said on Sunday morning that his company's trial of 30,000 people given a COVID vaccination was progressing well and he was optimistic.Albert Bourla, the CEO of Pfizer, said on Sunday morning that his company's trial of 30,000 people given a COVID vaccination was progressing well and he was optimistic.

Pfizer CEO says they could know if coronavirus vaccine works by the end of October | Daily Mail Online

The companies said in a statement Saturday that they expect to enroll the 30,000 patients they originally sought for its final-phase clinical trial this week

U.S. might have COVID-19 vaccine ready for Americans before year end: Pfizer CEO | National Post

U.S. might have COVID-19 vaccine ready for Americans before year end: Pfizer CEO | National Post

Upping the phase 3 investigational vaccine trial size to 44,000 participants will also allow for the enrollment of new populations.Upping the phase 3 investigational vaccine trial size to 44,000 participants will also allow for the enrollment of new populations.

Pfizer Phase 3 Coronavirus Vaccine Data Slated For October

BioNTech SE shares undefined soared 4% in premarket trade Tuesday, after the drug company said it will receive up to 375 million euros ($445.9 million) in...BioNTech SE shares undefined soared 4% in premarket trade Tuesday, after the drug company said it will receive up to 375 million euros ($445.9 million) in...

BioNTech shares jump premarket on news of 375 million euros in German funding for COVID-19 vaccine - MarketWatch

On Monday, Pfizer began a two-day investor presentation to show how it will become a growth stock.On Monday, Pfizer began a two-day investor presentation to show how it will become a growth stock.

Pfizer Highlights Dozens of Drugs in Its Pipeline. Here’s What It Means for the Stock. | Barron's

Germany awarded $745 million in funding to biotech firms BioNTech and CureVac on Tuesday to speed up work on COVID-19 vaccines and expand German production capacity.Germany awarded $745 million in funding to biotech firms BioNTech and CureVac on Tuesday to speed up work on COVID-19 vaccines and expand German production capacity.

Germany grants BioNTech, CureVac $745 million to speed up COVID-19 vaccine work | Reuters

Bloomberg - Are you a robot?

Approval of a vaccine, however, will depend on federal regulators, Albert Bourla said.

Pfizer CEO says company will know if vaccine works by end of October

Pfizer Inc (NYSE: PFE) and its German partner BioNTech SE (NASDAQ: BNTX) said Saturday they are seeking the United States Food and Drug Administration ...Pfizer Inc (NYSE: PFE) and its German partner BioNTech SE (NASDAQ: BNTX) said Saturday they are seeking the United States Food and Drug Administration approval to expand the late-...

Pfizer, Inc. (NYSE:PFE), Astrazeneca PLC (NYSE:AZN) - Pfizer Seeks FDA Nod To Expand Late-Stage COVID-19 Vaccine Trial | Benzinga

The head of German vaccine regulator today said it won't be less thorough when evaluating covid-19 vaccine applications.The head of German vaccine regulator today said it won't be less thorough when evaluating covid-19 vaccine applications.

Germany says covid vaccine approvals could come by end of this year

Germany will not take risky shortcuts when developing a vaccine against COVID-19, Research Minister Anja Karliczek said on Tuesday.Germany will not take risky shortcuts when developing a vaccine against COVID-19, Research Minister Anja Karliczek said on Tuesday.

Germany won't take risky short-cuts on COVID-19 vaccines—minister | Inquirer News

Pfizer's RNA-based Covid-19 vaccine candidate BNT162b2 which is being developed in partnership with BioNTech is set to enter Phase 3 human trials.

Coronavirus USA: When could Pfizer's vaccine start shipping? - AS.com

404 Not Found

BERLIN: German biotech firm BioNTech said on Tuesday (Sep 15) it had secured almost US$450 million in government funding to speed up work on its ...BERLIN: German biotech firm BioNTech said on Tuesday (Sep 15) it had secured almost US$450 million in government funding to speed up work on its ...

BioNTech wins US$445 million German grant for COVID-19 vaccine - CNA

The drugmaker's CEO said there was a more than 60% chance that they would know by the end of next month if BNT162b2 is effective.The drugmaker's CEO said there was a more than 60% chance that they would know by the end of next month if BNT162b2 is effective.

Pfizer says it could know if its COVID-19 vaccine candidate works in October // Motley Fool Australia

Pfizer and BioNTech’s vaccine is one of 35 potential inoculations currently in some phase of clinical testing, according to the WHO.Pfizer and BioNTech’s vaccine is one of 35 potential inoculations currently in some phase of clinical testing, according to the WHO.

Pfizer could have a vaccine ready by end of the year, says CEO Albert Bourla

NEW YORK (REUTERS) - Pfizer Inc said on Monday (Sept 14) that it had enrolled more than 29,000 people in its 44,000-volunteer trial to test the experimental Covid-19 vaccine it is developing with German partner BioNTech.. Read more at straitstimes.com.United States News -NEW YORK (REUTERS) - Pfizer Inc said on Monday (Sept 14) that it had enrolled more than 29,000 people in its 44,000-volunteer trial to test the experimental Covid-19 vaccine it is

Pfizer says enrolled more than 29,000 people in its Covid-19 vaccine trial, United States News & Top Stories - The Straits Times

GROTON, CT (WFSB) - The race to find a COVID-19 vaccine continues.GROTON, CT (WFSB) - The race to find a COVID-19 vaccine continues.

Pfizer aims to learn if its COVID-19 vaccine works by the end of October | News | wfsb.com

Pfizer CEO Albert Bourla to CBS: Will know coronavirus vaccine status by OctoberAlbert Bourla, the head of pharmaceutical giant Pfizer, which is among the companies developing a coronavirus vaccine, said that there is a 'good chance' the company will know whether its vaccine works by the end of October.

Pfizer CEO Albert Bourla to CBS: Will know coronavirus vaccine status by October | World News – India TV

Pfizer’s CEO says the pharmaceutical giant should know how effective its experimental COVID-19 vaccine will be by the end of October.Pfizer’s CEO says the pharmaceutical giant should know how effective its experimental COVID-19 vaccine will be by the end of October.

Pfizer CEO expects vaccine trial results before November | WOODTV.com

In a weekend interview on CBS’ “Face the Nation,” Albert Bourla, chief executive officer of Pfizer indicated they may have key data from its Phase III trial of the vaccine to the U.S. Food and Drug Administration by the end of October. In a weekend interview on CBS’ “Face the Nation,” Albert Bourla, chief executive officer of Pfizer indicated they may have key data from its Phase III trial of the vaccine to the U.S. Food and Drug Administration by the end of October.

Pfizer, BioNTech Say COVID-19 Vaccine Might Be Ready by End of October | BioSpace

Pfizer CEO announced that the company's COVID-19 vaccine may be ready by the year-end if things go well while adding that it is already being mass-produced.Pfizer CEO announced that the company's COVID-19 vaccine may be ready by the year-end if things go well while adding that it is already being mass-produced.

COVID-19 vaccine manufacturing has begun at a risk, will be ready by year-end: Pfizer CEO - Republic World

Pfizer CEO, Albert Boula, has said the drug company could release a coronavirus vaccine before the year is out if approved by the FDA.Pfizer CEO, Albert Boula, has said the drug company could release a coronavirus vaccine before the year is out if approved by the FDA.

Pfizer could have working Covid-19 vaccine before the end of 2020 | Buzz.ie

Here are all the latest updates on COVID-19 vaccine candidates.Here are all the latest updates on COVID-19 vaccine candidates.

Coronavirus vaccine update September 14 | Check out all COVID-19 vaccine updates from around the world

Fox News medical contributor Dr. Marc Siegel said Monday that the common flu, unlike coronavirus, is a "moving target" that often changes form from year to year, while COVID is more static in that regard.Fox News medical contributor Dr. Marc Siegel said Monday that the common flu, unlike coronavirus, is a "moving target" that often changes form from year to year, while COVID is more static in that regard.

Pharmaceutical giant Pfizer will likely know by the end of next month if its coronavirus vaccine is effective, CEO Albert Bourla said.Pharmaceutical giant Pfizer will likely know by the end of next month if its coronavirus vaccine is effective, CEO Albert Bourla said.

Pfizer should know if COVID vaccine works by end of October

Breaking News, Latest News and Current News from OANN.com. Breaking news and video. Latest Current News: U.S., World, Entertainment, Health, Business, Technology, Politics, Sports.

Pfizer says their vaccine will likely be approved by end of year | One America News Network

The race for a coronavirus vaccine shows no signs of slowing as more companies move their vaccine candidates through clinical trials, growing closer to determining which will be considered safe and effective.The race for a coronavirus vaccine shows no signs of slowing as more companies move their vaccine candidates through clinical trials, growing closer to determining which will be considered safe and effective.

Pfizer proposes expanding Covid-19 vaccine trial to include more diversity as race for a vaccine continues :: WRAL.com

Drugmaker Pfizer could know before the November election whether its coronavirus vaccine is safe and effective.Drugmaker Pfizer could know before the November election whether its coronavirus vaccine is safe and effective.

Pfizer COVID-19 vaccine may be ready for approval by October, CEO says

Pfizersays its coronavirus vaccine being developed in partnership with BioNTech could be given to Americans before the end of this year if trials succeed.Pfizersays its coronavirus vaccine being developed in partnership with BioNTech could be given to Americans before the end of this year if trials succeed.

CBS host Brennan wanted Bourla to say for the record that there is zero chance Americans can get a vaccine shot by the end of the year, but he would not say it.CBS host Brennan wanted Bourla to say for the record that there is zero chance Americans can get a vaccine shot by the end of the year, but he would not say it.

Pfizer CEO: We'll Know if Vaccine Works By End of October

"We have already manufactured hundreds of thousands of doses," Pfizer head Albert Bourla said."We have already manufactured hundreds of thousands of doses," Pfizer head Albert Bourla said.

Pfizer Has COVID-19 Vaccine In Production, Says Rejecting Federal Funding Gave Scientists Freedom

Access Denied

Pfizer, along with Moderna and AstraZeneca, is one of three companies currently in late-stage testing for a novel coronavirus vaccine.Pfizer, along with Moderna and AstraZeneca, is one of three companies currently in late-stage testing for a novel coronavirus vaccine.

Coronavirus: Pfizer vaccine could be distributed by year’s end, CEO says

Coronavirus, COVID-19 Vaccine Tracker India Today Latest News Update: Pfizer’s candidate, being developed in partnership with German company BioNTech, is one of the frontrunners in the race to produce a coronavirus vaccine, and is currently undergoing phase-3 trials in the United States.Coronavirus (COVID-19) vaccine tracker, September 14: Pfizer’s candidate, being developed in partnership with German company BioNTech, is one of the frontrunners in the race to produce a coronavirus vaccine.

Coronavirus (Covid-19) Vaccine Status Tracker Latest News Update Today: Covid shot likely to be available in America before year-end, says Pfizer CEO

While Bourla acknowledged the possibility Pfizer's vaccine candidate could fail, he argued that he doesn't believe any potential financial hit will "break the company" despite investing at least $1.5 billion in the effort.While Bourla acknowledged the possibility Pfizer's vaccine candidate could fail, he argued that he doesn't believe any potential financial hit will "break the company" despite investing at least $1.5 billion in the effort.

The company has already manufactured hundreds of thousands of doses in anticipation.The company has already manufactured hundreds of thousands of doses in anticipation.

Pfizer preparing to distribute COVID vaccine by year-end, CEO says - Axios

The companies said they plan to increase the size of the study to 44,000 participants, up from an initial goal of 30,000 individuals.The companies said they plan to increase the size of the study to 44,000 participants, up from an initial goal of 30,000 individuals.

Pfizer and BioNTech announce plan to expand Covid-19 vaccine trial

A conclusive result on the efficacy of the vaccine is likely by the end of OctoberA conclusive result on the efficacy of the vaccine is likely by the end of October

Pfizer, BioNTech to expand COVID-19 vaccine Phase 3 trial | Americas – Gulf News

Pharmaceutical company Pfizer is preparing for the likelihood of regulators approving the coronavirus vaccine the company is producing before the end of the year, CEO Albert Bourla said Sunday. Pharmaceutical company Pfizer is preparing for the likelihood of regulators approving the coronavirus vaccine the company is producing before the end of the year, CEO Albert Bourla said Sunday. 

Pfizer CEO 'preparing' for likelihood of vaccine approval before end of year | TheHill

Pharmaceutical company Pfizer is preparing for the likelihood of regulators approving the coronavirus vaccine the company is producing before the end of the year, CEO Albert Bourla said Sunday. Pharmaceutical company Pfizer is preparing for the likelihood of regulators approving the coronavirus vaccine the company is producing before the end of the year, CEO Albert Bourla said Sunday. 

Pfizer CEO 'preparing' for likelihood of vaccine approval before end of year | TheHill